康哲药业：磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评

Core Viewpoint - Kangzheng Pharmaceutical announced that its subsidiary, Demai Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration of China for the new drug application of phosphor-lucotini cream for the treatment of mild to moderate atopic dermatitis [1] Group 1 - The product is intended for the local short-term treatment of mild to moderate atopic dermatitis in children aged 2 years and older, as well as adults [1] - The drug has been granted priority review status due to its compliance with pediatric medication requirements, which is expected to expedite the approval process [1] - Phosphor-lucotini cream was approved in China in January 2026 as a targeted therapy for vitiligo [1]